Polypid Ltd (PYPD)

$5.15 -0.01 (-0.19%)
Market Cap 98.47M
Revenue (ttm) 0.00
Net Income (ttm) -34.17M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 100,100
Avg Vol 222,038
Day's Range N/A - N/A
Shares Out 19.08M
Stochastic %K 27%
Beta 1.41
Analysts Strong Sell
Price Target $11.75

Company Profile

PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in precl...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 7 4719 5700
Address:
18 Hasivim Street, Petah Tikva, Israel
Finnish_boy
Finnish_boy Sep. 11 at 7:37 PM
$PYPD I would do pumping but no followers
1 · Reply
Finnish_boy
Finnish_boy Sep. 11 at 7:36 PM
$PYPD Promotion to bigger X names. Who writes e.g substacks. Or MicroCapClub. NRXS doubled without reason when CEO interview with MicroCapClub and MVC wrote articles and posted X posts. Otherwise, we can do nothing. Yes, approval will do some kind of re-rate.
0 · Reply
robbied61
robbied61 Sep. 11 at 6:17 PM
$PYPD ok i agree with u so how do we get to were we want to go does it re ajust on its own after approval?
0 · Reply
Finnish_boy
Finnish_boy Sep. 11 at 12:47 PM
$PYPD Imo price action is normal when nobody talks about this stock. If retail woke up, stock would be much higher. Also, some bigger players ignore this also bc not US or EU name. Under radar.
0 · Reply
robbied61
robbied61 Sep. 11 at 11:50 AM
$PYPD ok finish i believe ur conclusion are acurate and very well thought out how ever the crrent price leaves me some doubt we should be over 7 right as we speak i believe the company lacks mkt savy and exposure and mgt is aloof to this issue. I have spoken to mgt multiple times and they have focused on there fundamentals and i believe stock price is irrelevant to them they have everything they need in there eyes and unfortunately i believe. They are right!!
0 · Reply
Finnish_boy
Finnish_boy Sep. 11 at 11:24 AM
$PYPD I use 90% odds for approval and after approval $10-$15 (within weeks). I use 90% odds for expected label (colorectal). 🔸 Restricted label $10-$11 🔸 Colorectal label $14-$15 So CRL 10% risk but high odds for recovery within a year. (Resubmission) (risk of some extra dilution). Fair value can be $25-30 if you look at pipeline but markets can undervaluate this for long period. If you use zero expected value, the expected value is hugely positive.
0 · Reply
robbied61
robbied61 Sep. 11 at 10:25 AM
$PYPD i am not worried about getting aproval i give them 99 percent chance. Just trying to figure out were the value will be how will the street evaluate it or if they will even give a crap 💩 this stock is very puzzling to me hard to figure
1 · Reply
EscapePlan
EscapePlan Sep. 10 at 6:30 PM
$PYPD so, i just found that you can get a call spread for PYPD for FEb between 5 and 7.5 for 70 cents. That means you break even at 5.70 and if we exceed 7.5 it's a $18,000 gain on a $7,000 investment in 5 months. YOu'd have to get a share price of over $18 by feb to be better in shares and your downside is if the share price doesnt get above 6..... I'm in for $7,000. Maybe it'll backfire, but so long as we get some decent news in November i think this should sit nicely above $7.5. thoughts?
2 · Reply
Finnish_boy
Finnish_boy Sep. 10 at 3:32 PM
$PYPD MAA submission next week? Anyway in 2-3 weeks.
0 · Reply
robbied61
robbied61 Sep. 9 at 5:24 PM
$PYPD not sure i prefer shrooms
0 · Reply
Latest News on PYPD
PolyPid reports Q2 EPS (35c), consensus (38c)

2026-08-17T09:49:24.000Z - 26 days ago

PolyPid reports Q2 EPS (35c), consensus (38c)

PolyPid Earnings Call Transcript: Q2 2026

Aug 12, 2026, 8:30 AM EDT - 4 weeks ago

PolyPid Earnings Call Transcript: Q2 2026

PolyPid Earnings release: Q2 2026

Aug 12, 2026, 8:30 AM EDT - 4 weeks ago

PolyPid Earnings release: Q2 2026

PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Aug 12, 2026, 7:30 AM EDT - 4 weeks ago

PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results

PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026

Jul 30, 2026, 8:00 AM EDT - 6 weeks ago

PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026

PolyPid NDA acceptance ‘meets or exceeds’ expectations, says Roth Capital

2026-07-29T15:30:17.000Z - 6 weeks ago

PolyPid NDA acceptance ‘meets or exceeds’ expectations, says Roth Capital

PolyPid announces FDA acceptance of, priority review for D-PLEX100

2026-07-29T13:01:07.000Z - 6 weeks ago

PolyPid announces FDA acceptance of, priority review for D-PLEX100

PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀

Jul 29, 2026, 8:30 AM EDT - 6 weeks ago

PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀

PolyPid price target lowered to $12 from $13 at Craig-Hallum

2026-07-22T13:15:29.000Z - 7 weeks ago

PolyPid price target lowered to $12 from $13 at Craig-Hallum

Roth says Azurity deal validates D-PLEX100, sees limited near-term revenue

2026-07-21T19:00:15.000Z - 7 weeks ago

Roth says Azurity deal validates D-PLEX100, sees limited near-term revenue

PolyPid Stock (PYPD) Plummets Despite Deal With Azurity to Tackle Surgical Infections

2026-07-21T12:23:53.000Z - 7 weeks ago

PolyPid Stock (PYPD) Plummets Despite Deal With Azurity to Tackle Surgical Infections

PolyPid enters exclusive pact with Azurity Pharmaceuticals for D-PLEX100

2026-07-21T11:40:15.000Z - 7 weeks ago

PolyPid enters exclusive pact with Azurity Pharmaceuticals for D-PLEX100

PolyPid, Azurity sign surgical site infection drug deal

Jul 21, 2026, 7:31 AM EDT - 7 weeks ago

PolyPid, Azurity sign surgical site infection drug deal

PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada

Jul 21, 2026, 7:30 AM EDT - 7 weeks ago

PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada

PolyPid completes NDA submission to FDA for D-PLEX100

2026-06-01T14:27:56.000Z - 3 months ago

PolyPid completes NDA submission to FDA for D-PLEX100

PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀

Jun 1, 2026, 8:30 AM EDT - 3 months ago

PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀

PolyPid Transcript: Lytham Partners Spring 2026 Investor Conference

May 28, 2026, 11:30 AM EDT - 3 months ago

PolyPid Transcript: Lytham Partners Spring 2026 Investor Conference

PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference

May 20, 2026, 8:30 AM EDT - 3 months ago

PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference

PolyPid reports Q1 EPS (35c), consensus (43c)

2026-05-13T17:09:41.000Z - 4 months ago

PolyPid reports Q1 EPS (35c), consensus (43c)

PolyPid Earnings Call Transcript: Q1 2026

May 13, 2026, 8:30 AM EDT - 4 months ago

PolyPid Earnings Call Transcript: Q1 2026

PolyPid Earnings release: Q1 2026

May 13, 2026, 8:30 AM EDT - 4 months ago

PolyPid Earnings release: Q1 2026

PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results

May 13, 2026, 7:30 AM EDT - 4 months ago

PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results

PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026

May 6, 2026, 8:00 AM EDT - 4 months ago

PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026

PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting

Apr 28, 2026, 8:30 AM EDT - 4 months ago

PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting

PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026

Apr 13, 2026, 9:15 AM EDT - 5 months ago

PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

Mar 31, 2026, 8:30 AM EDT - 5 months ago

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

PolyPid granted $4.3M waiver from FDA for D-Plex application

2026-03-17T12:46:11.000Z - 5 months ago

PolyPid granted $4.3M waiver from FDA for D-Plex application

PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀'s New Drug Application

Mar 17, 2026, 8:30 AM EDT - 5 months ago

PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀'s New Drug Application

PolyPid Transcript: The Citizens Life Sciences Conference 2026

Mar 10, 2026, 1:40 PM EDT - 6 months ago

PolyPid Transcript: The Citizens Life Sciences Conference 2026

PolyPid Announces Participation in Upcoming Investor Conferences

Feb 25, 2026, 8:35 AM EST - 6 months ago

PolyPid Announces Participation in Upcoming Investor Conferences

PolyPid Earnings Call Transcript: Q4 2025

Feb 11, 2026, 8:30 AM EST - 7 months ago

PolyPid Earnings Call Transcript: Q4 2025

PolyPid Annual report: Q4 2025

Feb 11, 2026, 8:30 AM EST - 7 months ago

PolyPid Annual report: Q4 2025

PolyPid Earnings release: Q4 2025

Feb 11, 2026, 8:30 AM EST - 7 months ago

PolyPid Earnings release: Q4 2025

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

Feb 11, 2026, 7:30 AM EST - 7 months ago

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

PolyPid Slides: Investor presentation

Feb 11, 2026, 6:00 AM EST - 7 months ago

PolyPid Slides: Investor presentation

PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026

Jan 28, 2026, 8:00 AM EST - 7 months ago

PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026

PolyPid Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit

Jan 15, 2026, 10:30 AM EST - 8 months ago

PolyPid Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit

PolyPid appoints Story as Chairman of Board of Directors

2025-12-16T13:41:48.000Z - 9 months ago

PolyPid appoints Story as Chairman of Board of Directors

PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

Dec 16, 2025, 8:30 AM EST - 9 months ago

PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

PolyPid Transcript: KOL Event

Dec 10, 2025, 11:30 AM EST - 9 months ago

PolyPid Transcript: KOL Event

PolyPid receives pre-NDA meeting minutes for D-Plex supporting NDA submission

2025-12-03T13:35:51.000Z - 9 months ago

PolyPid receives pre-NDA meeting minutes for D-Plex supporting NDA submission

PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission

Dec 3, 2025, 8:30 AM EST - 9 months ago

PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission

PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025

Nov 25, 2025, 8:30 AM EST - 9 months ago

PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025

PolyPid Slides: Corporate Presentation

Nov 18, 2025, 7:00 AM EST - 9 months ago

PolyPid Slides: Corporate Presentation

PolyPid price target lowered to $9 from $10 at Roth Capital

2025-11-13T11:16:03.000Z - 10 months ago

PolyPid price target lowered to $9 from $10 at Roth Capital

PolyPid Earnings Call Transcript: Q3 2025

Nov 12, 2025, 8:30 AM EST - 10 months ago

PolyPid Earnings Call Transcript: Q3 2025

PolyPid Earnings release: Q3 2025

Nov 12, 2025, 8:30 AM EST - 10 months ago

PolyPid Earnings release: Q3 2025

PolyPid sees cash runway ‘well into’ 2026

2025-11-12T12:41:32.000Z - 10 months ago

PolyPid sees cash runway ‘well into’ 2026

PolyPid reports Q3 EPS (37c), consensus (52c)

2025-11-12T12:35:15.000Z - 10 months ago

PolyPid reports Q3 EPS (37c), consensus (52c)

PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 12, 2025, 7:30 AM EST - 10 months ago

PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results

PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"

Nov 6, 2025, 8:30 AM EST - 10 months ago

PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"

PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025

Oct 29, 2025, 8:30 AM EDT - 10 months ago

PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025

PolyPid Transcript: Lytham Partners Fall 2025 Investor Conference

Sep 30, 2025, 12:30 PM EDT - 11 months ago

PolyPid Transcript: Lytham Partners Fall 2025 Investor Conference

PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress

Sep 30, 2025, 8:45 AM EDT - 11 months ago

PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress

PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference

Sep 17, 2025, 8:44 AM EDT - 12 months ago

PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference

PolyPid completes Israeli Ministry of Health GMP inspection

2025-09-16T12:45:43.000Z - 12 months ago

PolyPid completes Israeli Ministry of Health GMP inspection

PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀

Sep 16, 2025, 8:30 AM EDT - 12 months ago

PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀

PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Sep 3, 2025, 8:30 AM EDT - 1 year ago

PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference

Sep 2, 2025, 8:30 AM EDT - 1 year ago

PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference

PolyPid price target lowered to $13 from $15 at Craig-Hallum

2025-08-14T13:30:37.000Z - 1 year ago

PolyPid price target lowered to $13 from $15 at Craig-Hallum

PolyPid price target raised to $10 from $9 at Roth Capital

2025-08-14T12:05:26.000Z - 1 year ago

PolyPid price target raised to $10 from $9 at Roth Capital

PolyPid Earnings Call Transcript: Q2 2025

Aug 13, 2025, 8:30 AM EDT - 1 year ago

PolyPid Earnings Call Transcript: Q2 2025

PolyPid Earnings release: Q2 2025

Aug 13, 2025, 8:30 AM EDT - 1 year ago

PolyPid Earnings release: Q2 2025

PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 13, 2025, 7:30 AM EDT - 1 year ago

PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results

PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

Aug 12, 2025, 8:00 AM EDT - 1 year ago

PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025

Jul 30, 2025, 8:00 AM EDT - 1 year ago

PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025

PolyPid Registration statement: Registration Filing

Jul 29, 2025, 8:00 AM EDT - 1 year ago

PolyPid Registration statement: Registration Filing

PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market

Jul 15, 2025, 8:00 AM EDT - 1 year ago

PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

Jun 16, 2025, 7:20 PM EDT - 1 year ago

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

PolyPid Slides: Corporate Presentation

Jun 12, 2025, 7:00 AM EDT - 1 year ago

PolyPid Slides: Corporate Presentation

PESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

Jun 11, 2025, 9:42 AM EDT - 1 year ago

PESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

PESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

Jun 11, 2025, 9:40 AM EDT - 1 year ago

PESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript

Jun 9, 2025, 8:54 AM EDT - 1 year ago

BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript

PolyPid Transcript: Status Update

Jun 9, 2025, 8:30 AM EDT - 1 year ago

PolyPid Transcript: Status Update

PolyPid Press release: Status Update

Jun 9, 2025, 8:30 AM EDT - 1 year ago

PolyPid Press release: Status Update

PolyPid Slides: Status Update

Jun 9, 2025, 8:30 AM EDT - 1 year ago

PolyPid Slides: Status Update

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

Jun 9, 2025, 7:30 AM EDT - 1 year ago

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

PolyPid Slides: Investor Presentation

Jun 9, 2025, 7:00 AM EDT - 1 year ago

PolyPid Slides: Investor Presentation

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

Jun 6, 2025, 4:05 PM EDT - 1 year ago

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data Readout

May 30, 2025, 10:12 AM EDT - 1 year ago

PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data Readout

PolyPid Transcript: Lytham Partners Spring 2025 Investor Conference

May 29, 2025, 10:15 AM EDT - 1 year ago

PolyPid Transcript: Lytham Partners Spring 2025 Investor Conference

PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

May 20, 2025, 7:00 AM EDT - 1 year ago

PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

PolyPid Earnings Call Transcript: Q1 2025

May 14, 2025, 8:30 AM EDT - 1 year ago

PolyPid Earnings Call Transcript: Q1 2025

PolyPid Earnings release: Q1 2025

May 14, 2025, 8:30 AM EDT - 1 year ago

PolyPid Earnings release: Q1 2025

PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 14, 2025, 7:00 AM EDT - 1 year ago

PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025

Apr 29, 2025, 7:00 AM EDT - 1 year ago

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025

PolyPid to Participate in The Citizens Life Sciences Conference

Apr 22, 2025, 7:00 AM EDT - 1 year ago

PolyPid to Participate in The Citizens Life Sciences Conference

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Mar 11, 2025, 7:00 AM EDT - 1 year ago

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid to Participate in the 37th Annual ROTH Conference

Mar 3, 2025, 7:00 AM EST - 1 year ago

PolyPid to Participate in the 37th Annual ROTH Conference

PolyPid Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Feb 12, 2025, 11:20 AM EST - 1 year ago

PolyPid Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

PolyPid Earnings Call Transcript: Q4 2024

Feb 12, 2025, 8:30 AM EST - 1 year ago

PolyPid Earnings Call Transcript: Q4 2024

PolyPid Annual report: Q4 2024

Feb 12, 2025, 8:30 AM EST - 1 year ago

PolyPid Annual report: Q4 2024

PolyPid Earnings release: Q4 2024

Feb 12, 2025, 8:30 AM EST - 1 year ago

PolyPid Earnings release: Q4 2024

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Feb 12, 2025, 7:00 AM EST - 1 year ago

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 30, 2025, 7:00 AM EST - 1 year ago

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025

Jan 29, 2025, 7:00 AM EST - 1 year ago

PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025

PolyPid Registration statement: Registration Filing

Jan 21, 2025, 7:00 AM EST - 1 year ago

PolyPid Registration statement: Registration Filing

PolyPid Slides: Corporate Presentation

Jan 14, 2025, 6:00 PM EST - 1 year ago

PolyPid Slides: Corporate Presentation

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million

Dec 23, 2024, 7:22 PM EST - 1 year ago

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million

PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy

Dec 11, 2024, 7:00 AM EST - 1 year ago

PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy

PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

Nov 29, 2024, 1:05 PM EST - 1 year ago

PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

Finnish_boy
Finnish_boy Sep. 11 at 7:37 PM
$PYPD I would do pumping but no followers
1 · Reply
Finnish_boy
Finnish_boy Sep. 11 at 7:36 PM
$PYPD Promotion to bigger X names. Who writes e.g substacks. Or MicroCapClub. NRXS doubled without reason when CEO interview with MicroCapClub and MVC wrote articles and posted X posts. Otherwise, we can do nothing. Yes, approval will do some kind of re-rate.
0 · Reply
robbied61
robbied61 Sep. 11 at 6:17 PM
$PYPD ok i agree with u so how do we get to were we want to go does it re ajust on its own after approval?
0 · Reply
Finnish_boy
Finnish_boy Sep. 11 at 12:47 PM
$PYPD Imo price action is normal when nobody talks about this stock. If retail woke up, stock would be much higher. Also, some bigger players ignore this also bc not US or EU name. Under radar.
0 · Reply
robbied61
robbied61 Sep. 11 at 11:50 AM
$PYPD ok finish i believe ur conclusion are acurate and very well thought out how ever the crrent price leaves me some doubt we should be over 7 right as we speak i believe the company lacks mkt savy and exposure and mgt is aloof to this issue. I have spoken to mgt multiple times and they have focused on there fundamentals and i believe stock price is irrelevant to them they have everything they need in there eyes and unfortunately i believe. They are right!!
0 · Reply
Finnish_boy
Finnish_boy Sep. 11 at 11:24 AM
$PYPD I use 90% odds for approval and after approval $10-$15 (within weeks). I use 90% odds for expected label (colorectal). 🔸 Restricted label $10-$11 🔸 Colorectal label $14-$15 So CRL 10% risk but high odds for recovery within a year. (Resubmission) (risk of some extra dilution). Fair value can be $25-30 if you look at pipeline but markets can undervaluate this for long period. If you use zero expected value, the expected value is hugely positive.
0 · Reply
robbied61
robbied61 Sep. 11 at 10:25 AM
$PYPD i am not worried about getting aproval i give them 99 percent chance. Just trying to figure out were the value will be how will the street evaluate it or if they will even give a crap 💩 this stock is very puzzling to me hard to figure
1 · Reply
EscapePlan
EscapePlan Sep. 10 at 6:30 PM
$PYPD so, i just found that you can get a call spread for PYPD for FEb between 5 and 7.5 for 70 cents. That means you break even at 5.70 and if we exceed 7.5 it's a $18,000 gain on a $7,000 investment in 5 months. YOu'd have to get a share price of over $18 by feb to be better in shares and your downside is if the share price doesnt get above 6..... I'm in for $7,000. Maybe it'll backfire, but so long as we get some decent news in November i think this should sit nicely above $7.5. thoughts?
2 · Reply
Finnish_boy
Finnish_boy Sep. 10 at 3:32 PM
$PYPD MAA submission next week? Anyway in 2-3 weeks.
0 · Reply
robbied61
robbied61 Sep. 9 at 5:24 PM
$PYPD not sure i prefer shrooms
0 · Reply
Finnish_boy
Finnish_boy Sep. 9 at 4:41 PM
$PYPD How drunk is drunk enough?
0 · Reply
robbied61
robbied61 Sep. 9 at 1:19 PM
$PYPD after approval here's what i think moves the stock. Management thinks eropean fda in December filing and euro partner same deal structure in q 1 mgt touting not me pumping. If thats ok with you
0 · Reply
Seminamename1984
Seminamename1984 Sep. 9 at 5:10 AM
$PYPD IMO $12–18 requires approval, a commercially viable label, and a promising sales launch. $20–30 requires evidence of a substantial, profitable business. In my view, FDA approval alone wouldn’t justify the latter range.
1 · Reply
robbied61
robbied61 Sep. 8 at 5:13 PM
$PYPD feisty
1 · Reply
TheSuper
TheSuper Sep. 8 at 2:46 PM
$PYPD Every stock has to have an obsessive pumper who doesn't know how to act. How to identify: -Usually acts like a bitch. -Never hits price predictions. -Upset because you own a better position than them. -Is or acts like its their first win. -Thinks the board owes them something from their obsessive posting. -Hides behind their keyboard.
1 · Reply
Finnish_boy
Finnish_boy Sep. 8 at 2:26 PM
$PYPD +$11 dumb. Initial reaction. Learn to read messages.
1 · Reply
TheSuper
TheSuper Sep. 8 at 1:55 PM
$PYPD saw a comment by a person say $11 at approval. If this only hits $11 at approval it will be one of the poorest performing phase 3 -> approval stocks I have ever witnessed..... Especially considering the TAM, parntership, total share count, and runway. I don't know who is sitting in bio stocks for 1 year plus for 100% to 200% gain max.... but you are doing it wrong. I bet this goes $20+
1 · Reply
robbied61
robbied61 Sep. 7 at 4:00 PM
$PYPD gotta tell u have held this a long time missing other opportunities. Here comes our turn i am so dam enthusiastic can hardly wait for thenext couple of months, oh yeah after that it will even get better
0 · Reply
PaulNipkow
PaulNipkow Sep. 6 at 7:08 PM
$PYPD Only the hidden gems in Bio are up to 10+ baggers. So let's keep this one under the radar for now.
0 · Reply
robbied61
robbied61 Sep. 5 at 2:17 PM
$PYPD finish boy ditto
0 · Reply
Finnish_boy
Finnish_boy Sep. 4 at 9:36 PM
$PYPD Big October-November ahead. Keep holding and be patient. 3 months anymore to PDUFA. MAA submssion this month. I expect $8.0 by PDUFA. After PDUFA +$11.
1 · Reply
YoBee
YoBee Sep. 4 at 7:28 PM
$PYPD I created an investor presentation today, check it out: https://www.reddit.com/r/Polypid_Investors/s/fynRkpaLvD
0 · Reply